

NOVEMBER
2013

Health Canada approves Opsumit (macitentan) for sale in Canada for the treatment of PAH

MARCH
2014

Health Canada approves Adempas (riociguat) for sale in Canada for the treatment of PAH

OCTOBER
2014

INESSS recommends Opsumit be added to the list of drugs covered by the prescription drug insurance plan and Quebec begins providing public reimbursement for Opsumit

JANUARY
2015

Common Drug Review (CDR) recommends Opsumit be publicly funded (with criteria and a condition) for the long-term treatment of PAH to reduce morbidity in patients with Functional Class II or III

FEBRUARY
2015

INESSS recommends Adempas not be added to the list of drugs covered by the prescription drug insurance plan and Quebec declines to list Adempas for public funding

MARCH
2015

The *CADTH Therapeutic Review Recommendation Report of Drugs for PAH* recommends a suboptimal stepped approach to initial PAH therapy

JUNE
2015

PHA Canada launches an advocacy campaign to ensure all PAH patients have publicly funded access to new and existing treatments at diagnosis and beyond; PHA Canada Ambassadors begin meeting with their local provincial government representatives

SEPTEMBER
2015

Scleroderma Canada (SC) launches an advocacy campaign during National Scleroderma Conference and distributes advocacy postcards to systemic scleroderma-associated PAH (SSc-PAH) patients and supporters across Canada addressed to the provincial Ministers of Health

NOVEMBER
2015

SC and Scleroderma Association of Saskatchewan meet with the Saskatchewan Health Minister to discuss the importance of access to Opsumit for PAH patients, including those with SSc-PAH

DECEMBER 3
2015

PHA Canada and SC host an advocacy day at Queen's Park for Ontarians affected by PAH, including those with SSc-PAH

DECEMBER
2015

CDR recommends Adempas be publicly funded (with criteria and a condition) for the treatment of PAH as monotherapy or in combination with ERAs in adult patients with Functional Class II or III

DECEMBER
2015

Provincial and territorial negotiations for Opsumit through the pan-Canadian Pharmaceutical Alliance (pCPA) are closed without coming to an agreement

JANUARY
2016

Health Canada approves Upravi (selexipag) for sale in Canada for the treatment of PAH

FEBRUARY
2016

PHA Canada and SC call on pCPA to re-open negotiations for Opsumit without further delay to ensure that all patients living with PAH, including those with SSc-PAH, have publically funded access to optimal treatment for their life-threatening disease

JUNE
2016

MPP Michael Harris delivers 833 postcards from PAH, including SSc-PAH, supporters in Ontario to Honourable Dr. Eric Hoskins, Minister of Health and Long-Term Care

JUNE
2016

SC and Scleroderma Association of Saskatchewan have second meeting with the Saskatchewan Health Minister and deliver 106 postcards from PAH, including SSc-PAH, supporters in the province

JULY
2016

PHA Canada submits recommendations for improving funding criteria for PAH, including SSc-PAH, treatments to Ontario's Ministry of Health and Long-Term Care

OCTOBER
2016

Saskatchewan declines to list Adempas for public funding

OCTOBER
2016

INESSS recommends Upravi not be added to the list of drugs covered by the prescription drug insurance plan and Quebec declines to list Upravi for public funding

OCTOBER
2016

CDR recommends Upravi be publicly funded (with a criterion and a condition) for the long-term treatment of PAH, to delay disease progression in adult patients with Functional Class II or III